Lokesh Mehta

Advangelists - a Mobiquity Technologies Company

๐Ÿ“ San Francisco Bay Area, United States๐Ÿ”„ Updated September 2026๐Ÿ’ผ 1 investments๐Ÿ“… 7 years investing๐Ÿ—“ Last invested Apr 2019
VC๐ŸŒ United States
1
Total investments
0
Early stage
1
Mid stage
0
Late stage
7y
Years active

Portfolio

1 investments ยท sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Apr 2019
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. We use a patent pending, machine learning technology called Contingent-AIโ„ข to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction. We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research. We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. #ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech
mid stageBiotechnology
Experience ยท 2 entries
All (2)
Investments (1)
2019
Stealth Startup in OTT/CTV
Advisor
Oct 2019
Investor
Apr 2019
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. We use a patent pending, machine learning technology called Contingent-AIโ„ข to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction. We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research. We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. #ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech
mid stageBiotechnology